Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mapping gray and white matter volume abnormalities in early-onset psychosis: an ENIGMA multicenter voxel-based morphometry study

  • Si, Shuqing
  • Tordesillas-Gutiérrez, Diana
S. Si et al., [Introduction] Regional gray matter (GM) alterations have been reported in early-onset psychosis (EOP, onset before age 18), but previous studies have yielded conflicting results, likely due to small sample sizes and the different brain regions examined. In this study, we conducted a whole brain voxel-based morphometry (VBM) analysis in a large sample of individuals with EOP, using the newly developed ENIGMA-VBM tool., [Methods] 15 independent cohorts from the ENIGMA-EOP working group participated in the study. The overall sample comprised T1-weighted MRI data from 482 individuals with EOP and 469 healthy controls. Each site performed the VBM analysis locally using the standardized ENIGMA-VBM tool. Statistical parametric T-maps were generated from each cohort and meta-analyzed to reveal voxel-wise differences between EOP and healthy controls as well as the individual-based association between GM volume and age of onset, chlorpromazine (CPZ) equivalent dose, and other clinical variables., [Results] Compared with healthy controls, individuals with EOP showed widespread lower GM volume encompassing most of the cortex, with the most marked effect in the left median cingulate (Hedges’ g = 0.55, p = 0.001 corrected), as well as small clusters of lower white matter (WM), whereas no regional GM or WM volumes were higher in EOP. Lower GM volume in the cerebellum, thalamus and left inferior parietal gyrus was associated with older age of onset. Deficits in GM in the left inferior frontal gyrus, right insula, right precentral gyrus and right superior frontal gyrus were also associated with higher CPZ equivalent doses., [Conclusion] EOP is associated with widespread reductions in cortical GM volume, while WM is affected to a smaller extent. GM volume alterations are associated with age of onset and CPZ equivalent dose but these effects are small compared to case-control differences. Mapping anatomical abnormalities in EOP may lead to a better understanding of the role of psychosis in brain development during childhood and adolescence., MB is supported by a NHMRC Senior Principal Research Fellowship and Leadership 3 Investigator grant (1156072 and 2017131). The Hospital Clinic Barcelona - IDIBAPS cohort has been supported by the following funding agencies: the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, (PI18/00976, PI20/00654, PI02100330), Ajut a la Recerca Pons Bartran, the Alicia Koplowitz Foundation, Brain and Behavior Research Foundation (NARSAD Young Investigator Award 2017) and Strategic Research and Innovation Plan in Health (PERIS), Department of Health, Government of Catalonia. CA, CDC and JJ are supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union - NextGenerationEU (PMP21/00051), PI19/01024, PI20/00721, JR19/00024. CIBERSAM, Madrid Regional Government (S2022/BMD-7216 (AGES 3-CM)), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. YTOP cohort is supported by The Research Council of Norway (223273, 213700, 250358, 288083, 334326); South-Eastern Norway Regional Health Authority (2017112); KG Jebsen Stiftelsen (SKGJ-MED-008). SCAPS cohort is supported by The Swedish Research Council (521-2014-3487, 2017-00949); FORMAS (259-2012-31). RUND cohort is supported by South-Eastern Norway Regional Health Authority (#2004-259, # 2006-186). MPP is supported by the grant RYC2021‐031228‐I funded by MCIN/AEI/10.13039/50110 0011033 and by the “European Union NextGenerationEU/ PRTR”. PM’s work has been partially funded by National funds, through the Foundation for Science and Technology (FCT) - project UIDB/50026/2020 and UIDP/50026/2020 and by the project NORTE-01-0145-FEDER-000039, supported by Norte Portugal Regional Operational Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). The study was partially funded by the Italian Ministry of Health, Ricerca Corrente 23. SIT, NJ, PMT were supported in part by NIH grants: R01AG059874, R01MH134004, R01MH116147, R01MH121246, and P41EB015922. JJC is supported by a National Health and Medical Research Council (NHMRC) Emerging Leadership EL1 Fellowship (2008197). IBH is supported by a National Health and Medical Research Council (NHMRC) Leadership 3 Fellowship (2016346)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interplay Between Childhood Maltreatment, Subclinical Post-Traumatic Stress Symptoms, and IQ: Findings From the EU-GEI Multicentre Case–Control Study

  • Sideli, Lucia
  • Aas, Monica
  • Alameda, Luis
  • Trotta, Giulia
  • La Barbera, Daniele
  • La Cascia, Caterina
  • Ferraro, Laura
  • Velthorst, Eva
  • Tripoli, Giada
  • Schimmenti, Adriano
  • Fontana, Andrea
  • Quattrone, Diego
  • Gayer-Anderson, Charlotte
  • Rodriguez, Victoria
  • Spinazzola, Edoardo
  • Stilo, Simona
  • Seminerio, Fabio
  • Sartorio, Crocettarachele
  • Marrazzo, Giovanna
  • Lasalvia, Antonio
  • Tosato, Sarah
  • Tarricone, Ilaria
  • D'Andrea, Giuseppe
  • Amoretti, Silvia
  • Andreu-Bernabeu, Álvaro
  • Baudin, Grégoire
  • Beards, Stephanie
  • Bonetto, Chiara
  • Bonora, Elena
  • Cabrera, Bibiana
  • Carracedo, Angel
  • Charpeaud, Thomas
  • Costas, Javier
  • Cristofalo, Doriana
  • Durán-Cutilla, Manuel
  • Ferchiou, Aziz
  • Fraguas, David
  • Franke, Nathalie
  • Frijda, Flora
  • Llorente, Cloe
  • Garcia-Portilla, Paz
  • González Peñas, Javier
  • Hubbard, Kathryn
  • Jamain, Stéphane
  • Jiménez-López, Estela
  • Leboyer, Marion
  • López Montoya, Gonzalo
  • Lorente-Rovira, Esther
  • Díaz-Caneja, Covadonga M.
  • Marcelino Loureiro, Camila
  • Mayoral, Maria
  • Merchan, Jessica
  • Moreno, Dolores M.
  • Messchaart, Elles
  • Moltó, Ma Dolores
  • Mezquida, Gisela
  • Moreno, Carmen
  • Muratori, Roberto
  • Juan, Nacher
  • Parellada, Mara
  • Rapado-Castro, Marta
  • Ruggeri, Mirella
  • Richard, Jean Romain
  • Solano, Rodríguez
  • Juan, José
  • Sáiz, Pilar A.
  • Sánchez-Gutierrez, Teresa
  • Sánchez, Emilio
  • Franck, Schürhoff
  • Seri, Marco
  • Shuhama, Rosana
  • Termorshuizen, Fabian
  • Tronche, Anne Marie
  • van Dam, Daniella
  • van der Ven, Elsje
  • Arango, Celso
  • Arrojo, Manuel
  • Bernardo, Miguel
  • Bobes, Julio
  • Sanjuán, Julio
  • Santos, Jose Luis
  • Menezes, Paulo Rossi
  • Del-Ben, Cristina Marta
  • Jongsma, Hannah E.
  • Jones, Peter B.
  • Kirkbride, James B.
  • Llorca, Pierre Michel
  • Tortelli, Andrea
  • Pignon, Baptiste
  • de Haan, Lieuwe
  • Selten, Jean Paul
  • Van Os, Jim
  • Rutten, Bart P.
  • Di Forti, Marta
  • Murray, Robin M.
  • Morgan, Craig
  • Fisher, Helen L.
  • EU-GEI WP2 Group
EU-GEI WP2 Group The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) WP2 Group members includes: Silvia Amoretti, PhD, Barcelona Clinic Schizophrenia Unit, Hospital Clinic, Departament de Medicina, Institut de Neurociències (UBNeuro), Universitat de Barcelona (UB), Institut d'Investigacions Biomèdiques, August Pi I Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; Álvaro Andreu-Bernabeu, Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain; Grégoire Baudin, MSc, AP-HP, Groupe Hospitalier ‘Mondor’, Pôle de Psychiatrie, Créteil, France, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France; Stephanie Beards, PhD, Department of Health Service and Population Research, Institute of Psychiatry, King's College London, London, England; Chiara Bonetto, PhD, Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy; Elena Bonora, PhD, Department of Medical and Surgical Science, Genetic Unit, Alma Mater Studiorium Università di Bologna, Bologna, Italy; Bibiana Cabrera, MSc, PhD, Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Barcelona, Spain, CIBERSAM, Spain; Angel Carracedo, MD, PhD, Fundación Pública Galega de Medicina Xenómica, Hospital Clínico Universitario, CIBERER, Santiago de Compostela, Spain; Thomas Charpeaud, MD, Fondation Fondamental, Créteil, France, CMP B CHU, Clermont Ferrand, France and Université Clermont Auvergne, Clermont-Ferrand, France; Javier Costas, PhD, Fundación Pública Galega de Medicina Xenómica, Hospital Clínico Universitario, Santiago de Compostela, Spain; Doriana Cristofalo, MA, Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy; Manuel Durán-Cutilla, MD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Institute of Psychiatry and Mental Health, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain; Aziz Ferchiou, MD, AP-HP, Groupe Hospitalier ‘Mondor’, Pôle de Psychiatrie, Créteil, France, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France; David Fraguas, MD, PhD, Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Barcelona, Spain; Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Institute of Psychiatry and Mental Health, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain; Nathalie Franke, MSc, Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; Flora Frijda, MSc, Etablissement Public de Santé Maison Blanche, Paris, France; Cloe Llorente, MD, Department of Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Investigación Sanitaria del Hospital Gregorio Marañón (CIBERSAM), Madrid, Spain; Paz Garcia-Portilla, MD, PhD, Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, ISPA, INEUROPA, CIBERSAM, Oviedo, Spain; Javier González Peñas, Hospital Gregorio Marañón (CIBERSAM), IiSGM, School of Medicine, Madrid, Spain; Kathryn Hubbard, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London; Stéphane Jamain, PhD, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France, Faculté de Médecine, Université Paris-Est, Créteil, France and Fondation Fondamental, Créteil, France; Estela Jiménez-López, MSc, Department of Psychiatry, Servicio de Psiquiatría Hospital ‘Virgen de la Luz,’ Cuenca, Spain; Marion Leboyer, MD, PhD, AP-HP, Groupe Hospitalier ‘Mondor,’ Pôle de Psychiatrie, Créteil, France, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France, Faculté de Médecine, Université Paris-Est, Créteil, France and Fondation Fondamental, Créteil, France; Gonzalo López Montoya, PhD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM (CIBERSAM), Madrid, Spain; Esther Lorente-Rovira, PhD, Department of Psychiatry, School of Medicine, Universidad de Valencia, CIBERSAM, Valencia, Spain; Covadonga M. Díaz-Caneja, Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain; Camila Marcelino Loureiro, MD, Departamento de Neurociências e Ciencias do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brasil and Núcleo de Pesquina em Saúde Mental Populacional, Universidade de São Paulo, São Paulo, Brasil; Maria Mayoral, Institute of Psychiatry and Mental health, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IIiSGM, CIBERSAM, Madrid, Spain; Jessica Merchan, Institute of Psychiatry and Mental health, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IIiSGM, CIBERSAM, Madrid, Spain; Dolores M. Moreno, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM (CIBERSAM), Madrid, Spain; Elles Messchaart, MSc, Rivierduinen Centre for Mental Health, Leiden, the Netherlands; Ma Dolores Moltó, Department of Genetics, University of Valencia, Campus of Burjassot, Biomedical Research Institute INCLIVA, Valencia, Spain, Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Gisela Mezquida, PhD, Barcelona Clinic Schizophrenia Unit, Hospital Clinic, Departament de Medicina, Institut de Neurociències (UBNeuro), Universitat de Barcelona (UB), Institut d'Investigacions Biomèdiques, August Pi I Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; Carmen Moreno, MD, Department of Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM (CIBERSAM), Madrid, Spain; Roberto Muratori, MD, Department of Mental Health and Pathological Addiction, Local Health Authority, Bologna, Italy; Nacher Juan, Neurobiology Unit, Department of Cell Biology, Interdisciplinary Research Structure for Biotechnology and Biomedicine (BIOTECMED), Universitat de València, Valencia, Spain, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM): Spanish National Network for Research in Mental Health, Madrid, Spain, Fundación Investigación Hospital Clínico de Valencia, INCLIVA, Valencia, Spain; Mara Parellada, MD, PhD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM (CIBERSAM), Madrid, Spain; Marta Rapado-Castro, PhD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Institute of Psychiatry and Mental Health, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain; Mirella Ruggeri, MD, PhD, Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy; Jean-Romain Richard, MSc, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France and Fondation Fondamental, Créteil, France; Rodríguez Solano, José Juan, MD, Puente de Vallecas Mental Health Department, Hospital Universitario Infanta Leonor/Hospital Virgen de la Torre, Centro de Salud Mental Puente de Vallecas, Madrid, Spain; Pilar A. Sáiz, Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM. Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain; Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain; Teresa Sánchez-Gutierrez, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, C/Doctor Esquerdo 46, 28007 Madrid, Spain. Faculty of Health Science. Universidad Internacional de La Rioja (UNIR), Madrid, Spain; Emilio Sánchez, MD, Department of Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM (CIBERSAM), Madrid, Spain; Schürhoff, Franck, MD, PhD, AP-HP, Groupe Hospitalier ‘Mondor,’ Pôle de Psychiatrie, Créteil, France, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France, Faculté de Médecine, Université Paris-Est, Créteil, France and Fondation Fondamental, Créteil, France; Marco Seri, MD, Department of Medical and Surgical Science, Genetic Unit, Alma Mater Studiorium Università di Bologna, Bologna, Italy; Rosana Shuhama, PhD, Departamento de Neurociências e Ciencias do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brasil and Núcleo de Pesquina emSaúde Mental Populacional, Universidade de São Paulo, São Paulo, Brasil; Fabian Termorshuizen, PhD, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, the Netherlands and Rivierduinen Centre for Mental Health, Leiden, the Netherlands; Anne-Marie Tronche, MD, Fondation Fondamental, Créteil, France, CMP B CHU, Clermont Ferrand, France and Université Clermont Auvergne, ClermontFerrand, France; Daniella van Dam, PhD, Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; Elsje van der Ven, PhD, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience,n and Teaching Network, Maastricht University Medical Centre, Maastricht, the Netherlands and Rivierduinen Centre for Mental Health, Leiden, the Netherlands., [Introduction] Evidence suggests that childhood maltreatment affects cognitive performance in both patients with psychosis and community controls. However, the interplay between childhood maltreatment, post-traumatic stress symptoms (PTSS), and intelligence has not been investigated. This study investigated the relationship between childhood maltreatment, subclinical PTSS, and intelligence among patients with first-episode psychosis (FEP) and community controls., [Methods] Patients with FEP (N = 602) and controls (N = 853) from the EU-GEI study were assessed for childhood maltreatment, PTSS, and intelligence quotient (IQ)., [Results] PTSS were associated with lower IQ among community controls but not among patients with FEP. In the FEP group, an interaction (p = 0.044) between PTSS and childhood maltreatment on IQ was found, such that the association between PTSS and lower IQ was only present among those exposed to childhood maltreatment. No interaction was evident in controls (p = 0.826)., [Conclusions] The findings suggest the relevance of cognitive rehabilitation for FEP patients with childhood maltreatment and PTSS., The EU-GEI Study is funded by the European Community's Seventh Framework Programme [HEALTH-F2-2010-241909] (Project EU-GEI) and the São Paulo Research Foundation [2012/0417-0]. Monica Aas is supported by a Medical Research Council (MRC) fellowship [MR/W027720/1]. Luis Alameda was supported by fellowships from Fondation Adrian et Simone Frutiger and Carigest SA. Celso Arango has received support from the Spanish Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, European Regional Development Funds from the European Commission, ‘A way of making Europe’, financed by the European Union NextGenerationEU [PMP21/00051, PI19/01024, PI22/01824], CIBERSAM, Government of the Community of Madrid [B2017/BMD-3740, AGES-CM-2], European Union Structural Funds, European Union Seventh Framework Programme, European Union H2020 Programme under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 [101034377], Project AIMS-2-TRIALS [777394], Horizon Europe, the National Institute of Mental Health [1U01MH124639-01 ProNET, 5P50MH115846-03 FEP-CAUSAL], Fundación Familia Alonso and Fundación Alicia Koplowitz. Helen L. Fisher, Charlotte Gayer-Anderson and Craig Morgan are supported by the Economic and Social Research Council (ESRC) Centre for Society and Mental Health at King's College London [ES/S012567/1]. Diego Quattrone is supported by the MRC Clinical Academic Research Partnership [MR/W030608/1]. Edoardo Spinazzola was supported by Lord Leverhulme's Charitable Trust and the Velvet Foundation and by the MRC [MR/T007818/1]. Bart P. Rutten is funded by a VIDI award from the Dutch Research Council [91.718.336]. The views expressed are those of the authors and not necessarily those of the ESRC or King's College London. The members of EU-GEI WP2 Group are listed in Appendix A. Craig Morgan and Helen L. Fisher contributed equally to this work and they are joint senior authors., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploring the Impact of Schizophrenia and Its Pharmacological Treatment on Health-Related Quality of Life and Treatment Preferences

  • Arango, Celso
  • Baeza, Inmaculada
  • García-Rizo, Clemente
  • Crespo-Facorro, Benedicto
  • Lahera, Guillermo
  • Vieta, Eduard
  • Becker, Frauke
  • Dwyer, Georges
  • Bourke, Siobhan
  • Gibson, Adam
  • Gabarda-Inat, Irene
  • Álvarez-Baron, Elena
The abstract of this paper was presented at the 36th ECNP Congress 2023 (Barcelona 7-10 October) as a poster presentation with interim findings. The poster’s abstract was published in Abstracts of the 36th ECNP Congress 2023 in Neuroscience applied (Vol2, Supplement 2): https://doi.org/10.1016/j.nsa.2023.103062., [Purpose:] Pharmacological treatments play an important role in managing symptoms of schizophrenia but can also be associated with side effects. The aim of this study was to understand the impact of schizophrenia and its pharmacological treatment on patients’ health-related quality of life (HRQoL) and to explore patient preferences around treatment benefits and side effects., [Patients and Methods:] This study employed a mixed methods approach with two stages of recruitment of adult patients in Spain. Stage 1 included qualitative and quantitative elements (including included two validated patient-reported outcome measures: PETiT and EQ-5D-5L) administered in telephone interviews with people with schizophrenia. Stage 2 consisted of a quantitative online survey completed by people with schizophrenia attending outpatient clinics. Responses to quantitative items across both stages were combined for analysis., [Results:] Twenty respondents completed the mixed methods interviews (stage 1), and 25 participants completed the online survey (stage 2). Results from stages 1 and 2, showed that participants perceived treatments to have a beneficial impact on controlling their symptoms. However, cognitive side effects were reported to have a detrimental impact on respondents’ daily life and were considered a primary reason for treatment cessation in the past. Qualitative findings further showed that most participants hoped future treatments would minimise the impact of cognitive symptoms of schizophrenia., [Conclusion:] The findings suggest that patients’ expectation around treatment efficacy and their acceptability of treatment side effects may indicate their capacity to maintain long-term treatment adherence. Trade-offs that patients may be willing to make between these components may prove useful to consider in clinical practice to improve treatment adherence and hence treatment effectiveness in people with schizophrenia., CA has been supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union - NextGenerationEU (PMP21/00051), PI19/01024, PI22-01824.CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. IB has been supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (PI21/0391), co-financed by the European Union, Drugs National Plan (2022I053) and Fundación Alicia Koplowitz., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Biological underpinnings and genetic predisposition to schizophrenia within microrna-137 regulatory pathways across brain development

  • Stella, Carol
  • Hoyos, Lucía de
  • Mora, Alberto
  • Díaz-Caneja, Covadonga M.
  • Andreu-Bernabeu, Álvaro
  • Costas, Javier
  • Gurriarán, Xaquín
  • Fañanas, Lourdes
  • Bobes, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Vázquez-Bourgon, Javier
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Sánchez-Gistau, Vanessa
  • Moltó, Maria Dolores
  • Rivero, Olga
  • CIBERSAM consortium
  • Arango, Celso
  • González-Peñas, Javier
[Data availability] GWAS summary datasets used in this study have been downloaded from the PGC repository (https://www.med.unc.edu/pgc/download-results/). Gene expression data from brain developmental trajectories (http://www.brainspan.org/) and adult brain (https://gtexportal.org/home/) were downloaded from FUMA platform (https://fuma.ctglab.nl/). Individual genotype data for the CIBERSAM consortium samples (Spain, https://www.cibersam.es/en) used here and analytic code are available from the corresponding author upon reasonable request, since deposit of this data to a public repository is not allowed due to ethical and legal requirements at the participating centers., Previous studies have evaluated the role of the microRNA-137 (miRNA137) regulatory pathway in schizophrenia by using in silico or in vitro predicted target genes. These approaches do not capture the dynamic spatiotemporal nature of the miRNA137 regulatory pathway or tend to overestimate direct miRNA binding sites. To provide a more accurate representation of the miRNA137 pathway during human brain development, we evaluated the biological functionality of direct ex vivo miRNA137 targets previously documented in the early prenatal and adult brain. We studied the role of differential expression and genetic predisposing variation to schizophrenia and related disorders within these miRNA137 targets by gene set enrichment analyses (GSEA) and gene-set based polygenic score predictions in an independent schizophrenia case-control cohort. All results were compared to those from in silico or in vitro predicted targets. Only direct miRNA137 targets at prenatal and adult human brain displayed significant enrichments in synaptic and neuronal functions and captured the transcriptomic and genetic predisposing variation to schizophrenia. Furthermore, while adult target genes showed a more consistent enrichment in predisposing variation to schizophrenia and bipolar disorder in case/control polygenic models, prenatal target genes predicted negative symptomatology in schizophrenia patients. Our results suggest that using direct, temporally specific miRNA137 targets significantly improved the detection of biological mechanisms underlying its relationship with psychosis, clarified the association between schizophrenia and related conditions, and suggested association with specific symptomatology domains at different developmental stages of the disorder., Supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB/07/09/0023), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721, PI22/01824, PI23/00625), the European Union -NextGenerationEU (PMP21/00051), Madrid Regional Government (S2022/BMD-7216 AGES 3-CM), European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394)) European Union Horizon Europe Program (Project Youth-GEMs (Grant agreement No 101057182), the National Institute of Mental Health of the National Institutes of Health, Fundación Familia Alonso, and Fundación Alicia Koplowitz. González-Peñas held a Sara Borrell and a Miguel Servet grant during the development of the research from Instituto de Salud Carlos III (CD20/00118; CP24/00080-DOS). CM Díaz-Caneja has previously held a Juan Rodés Grant from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (JR19/00024)., Peer reviewed
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: results from the EUGEI study

  • Fusar Poli, L.
  • Prachason, T.
  • Erzin, G.
  • Bobes, Julio|||0000-0003-2187-4033
  • Saiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz|||0000-0003-3643-1622
  • Outcome of Psychosis (GROUP)
The EUGEI project was supported by the grant agreement HEALTHF2-2010-241909 from the European Community’s Seventh Framework Programme. Dr Arango was supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union - NextGenerationEU (PMP21/00051), PI19/01024. CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. Drs. Bobes, García-Portilla, and Sáiz have received partial support from the Government of the Principality of Asturias PCTI-2021-2023 IDI/2021/111, the Fundación para la Investigación e Innovación Biosanitaria del Principado de Asturias (FINBA), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovacion (...), Fusar-Poli, L., Prachason, T., Erzin, G., Pries, L.-K., Brondino, N., Politi, P., Delespaul, P., Kenis, G., Luykx, J.J., Lin, B.D., Richards, A.L., Akdede, B., Binbay, T., Altınyazar, V., Yalınçetin, B., Gümüş-Akay, G., Cihan, B., Soygür, H., Ulaş, H., Cankurtaran, E.Ş., Kaymak, S.U., Mihaljevic, M.M., Andric-Petrovic, S., Mirjanic, T., Bernardo, M., Mezquida, G., Amoretti, S., Bobes, J., Saiz, P.A., García-Portilla, M.P., Sanjuan, J., Escarti, M.J., Santos, J.L., Jiménez-López, E., Arrojo, M., Carracedo, A., López, G., González-Peñas, J., Parellada, M., Maric, N.P., Atbaşoğlu, C., Üçok, A., Alptekin, K., Saka, M.C., Arango, C., O'Donovan, M., van Os, J., Rutten, B.P., Guloksuz, S., Genetic Risk and Outcome of Psychosis (GROUP) investigators
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Biological underpinnings and genetic predisposition to schizophrenia within microrna-137 regulatory pathways across brain development

  • Stella, C.
  • Hoyos, L.
  • Mora A.
  • Bobes, Julio|||0000-0003-2187-4033
Supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB/07/09/0023), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721, PI22/01824, PI23/00625), the European Union -NextGenerationEU (PMP21/00051), Madrid Regional Government (S2022/BMD-7216 AGES 3-CM), European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394)) European Union Horizon Europe Program (Project Youth-GEMs (Grant agreement No 101057182) (...), Stella C., De Hoyos L., Mora A., Díaz-Caneja C.M., Andreu-Bernabeu Á., Costas J., Gurriarán X., Fañanas L., Bobes J., González-Pinto A., Crespo-Facorro B., Vázquez-Bourgon J., Martorell L., Vilella E., Muntané G., Sanchez-Gistau V., Moltó M.D., Rivero O., Arango C., Moreno C., Parellada M., David-Lluesma J., Escartí M.J., Rivero O., Moltó M.D., Muntané G., Vilella E., Martorell L., Crespo-Facorro B., González Pinto A., Bobes J., Arias B., de la Cruz A.R., Fañanas L., Arrojo M., Costas J., Díaz-Caneja C.M., González-Peñas J., Arango C.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

The role of social deprivation and cannabis use in explaining variation in the incidence of psychotic disorders: findings from the EU-GEI study

  • Brink, Vera
  • Andleeb, Humma
  • Gayer Anderson, Charlotte
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by the European Community’s Seventh Framework Program (HEALTH-F2-2010-241909 [Project EU-GEI]) and the São Paulo Research Foundation (2012/0417-0). C.A. was supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), the European Union, ERDF Funds from the European Commission, “A way of making Europe,” financed by the European Union—NextGenerationEU (PMP21/00051), PI19/01024. CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (101034377), Project AIMS-2-TRIALS (777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health (award numbers 1U01MH124639-01 [Project ProNET], 5P50MH115846-03 [project FEP-CAUSAL]), Fundación Familia Alonso, and Fundación Alicia Koplowitz. (...), Brink V., Andleeb H., Gayer-Anderson C., Arango C., Arrojo M., Berardi D., Bernardo M., Bobes J., Del-Ben C.M., Ferraro L., De Haan L., La Barbera D., La Cascia C., Lasalvia A., Llorca P.-M., Menezes P.R., Pignon B., Sanjuán J., Santos J.L., Selten J.-P., Tarricone I., Tortelli A., Tripoli G., Velthorst E., Rutten B.P.F., Van Os J., Quattrone D., Murray R.M., Jones P.B., Morgan C., Di Forti M., Jongsma H.E., Kirkbride J.B.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the eu-gei case-control and uk biobank studies

  • Austin Zimmerman, I.
  • Spinazzola, E.
  • Quattrone, D.
  • Bobes, Julio|||0000-0003-2187-4033
The EU-GEI project was funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI). Dr Arango receives support from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, ‘A way of making Europe’, financed by the European Union – NextGenerationEU (PMP21/00051), PI19/01024. CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (grant agreement No. 101034377), Project AIMS-2-TRIALS (grant agreement No. 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz (...), Austin-Zimmerman I., Spinazzola E., Quattrone D., Wu-Choi B., Trotta G., Li Z., Johnson E., Richards A.L., Freeman T.P., Tripoli G., Gayer-Anderson C., Rodriguez V., Jongsma H.E., Ferraro L., La Cascia C., Tosato S., Tarricone I., Berardi D., Bonora E., Seri M., D'Andrea G., Szöke A., Arango C., Bobes J., Sanjuán J., Santos J.L., Arrojo M., Velthorst E., Bernardo M., Del-Ben C.M., Rossi Menezes P., Selten J.-P., Jones P.B., Kirkbride J.B., Rutten B.P.F., Tortelli A., Llorca P.-M., De Haan L., Stilo S., La Barbera D., Lasalvia A., Schurnhoff F., Pignon B., Van Os J., Lynskey M., Morgan C., O' Donovan M., Lewis C.M., Sham P.C., Murray R.M., Vassos E., Di Forti M.